BIOVENTUS INC. — Earnings

Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR

Next earnings (estimated): Wed, April 1, 2026 32 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)

Recent earnings · last 8 quarters

Quarter endRevenueYoYNet IncomeYoYOp. Margin
2025-12-31$158M↑+2.8%$15M12.3%
2025-09-27$139M↓-0.2%$3M↑+161.1%8.1%
2025-06-28$148M↓-2.4%$7M↑+129.0%12.4%
2025-03-29$124M↓-4.3%$-3M↑+46.1%3.9%
2024-12-31$154M↑+13.5%
2024-09-28$139M↑+15.0%$-5M↑+29.3%2.6%
2024-06-29$151M↑+10.3%$-26M↓-597.7%-20.8%
2024-03-30$129M↑+8.7%$-5M↑+96.5%3.8%

Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.

Last earnings · FY2025 (Q4)

Revenue
$158M
↑+2.8% +$4M YoY
Net Income
$14M

Earnings surprise · last 8 quarters

YoY % change · proxy for analyst surprise until estimates land

EPS history · last 10 fiscal years

diluted, GAAP, annual

Note: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.

Margin trends · 26 quarters

margin trajectory tells the operating-leverage story
Gross Margin↑+2.1pts
68.9%
Operating Margin
12.3%
Net Margin
9.3%

Go deeper